Navigation Links
Statement from Lighthouse International About the Study on Gene Therapy Concerning Leber's Congenital Amaurosis
Date:4/29/2008

NEW YORK, April 29 /PRNewswire/ -- Lighthouse International is a leader in vision healthcare -- serving people who are visually impaired and partially sighted for 103 years.

According to Dr. Tara A Cortes, President and CEO of Lighthouse International:

"This is a dramatic breakthrough in gene therapy that could potentially impact other genetic eye diseases that affect children."

According to Yocasta Urena, 28, an employee of Lighthouse International who has Leber's Congenital Amaurosis and whose 4-year-old daughter has the same condition, "This research is a ray of hope for me and certainly for my daughter's future." Her daughter, Aolani Cruz, has been in the Lighthouse International Child Development Center (which educates children who are visually impaired and sighted) for a year and a half and has made significant progress.

Dr. Cortes continued, "In the decades to come, this therapy may also have implications for other serious eye diseases such as Age Related Macular Degeneration, which has been found to have a genetic link and affects some 9 million Americans and millions abroad.

There is a vision loss epidemic in the United States which affects millions. Research and vision rehabilitation & services will also be needed to address this growing national health problem."

Founded in 1905, Lighthouse International is a leading non-profit organization dedicated to preserving vision and providing critically needed health care services to help people of all ages overcome the challenges of vision loss. Through services, education, research and advocacy, the Lighthouse enables people with low vision and blindness to enjoy safe, independent and productive lives. For more information about vision loss, its causes and what you can do about it, contact Lighthouse International at 1-800-829-0500 or visit http://www.lighthouse.org.


'/>"/>
SOURCE Lighthouse International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will showcase ... demos and poster sessions, and present on the analysis of mycotoxins and medical ... 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... PARK, Calif. , Feb. 4, 2016   DelMar ... biopharmaceutical company focused on the development and commercialization of new ... 18 th Annual BIO CEO & Investor Conference ... in New York, NY . ... an update on the ongoing clinical trial of VAL-083 ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):